Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 3/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
| ▸ | GUSB | P08236 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20746967 | 0.82 | EBP (0.37) | EBPSIGMAR1FDPSLMNADNM1 | |
| SCHEMBL19711201 | 0.79 | EBP (0.39) | EBPSIGMAR1FDPSGBA1LMNA | |
| SCHEMBL21846657 | 0.79 | EBP (0.35) | EBPSIGMAR1FDPSLMNADNM1 | |
| SCHEMBL24562872 | 0.79 | DNM1 (0.33) | FDPSGBA1LMNADNM1 | |
| SCHEMBL17793809 | 0.75 | — | — | |
| SCHEMBL23844581 | 0.74 | CHRNB2 (0.38) | EBPSIGMAR1FDPSGBA1LMNA | |
| SCHEMBL23844840 | 0.74 | CHRNB2 (0.38) | EBPSIGMAR1FDPSGBA1LMNA | |
| SCHEMBL18948436 | 0.74 | PRKD3 (0.38) | EBPSIGMAR1GBA1GUSB | |
| SCHEMBL23969782 | 0.73 | EBP (0.31) | EBPSIGMAR1FDPS | |
| SCHEMBL24599522 | 0.73 | EBP (0.31) | EBPSIGMAR1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | BMP1, BMP2, BMPR2 | EBP 198/4885SIGMAR1 4657/4885FDPS 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.